KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study.

Kevin J Blinder, Charles C Wykoff, Joseph R Ferencz, Justis P Ehlers, Yixin Fang, Hongxin Lai, Miller Ogidigben, Francisco J López

Retina 45(12) 2252-2262

PMID40712145
PMCID-
DOI10.1097/IAE.0000000000004623
发表日期2025-07-25
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: To evaluate the effects of dexamethasone intravitreal implant (DEX) treatment on Diabetic Retinopathy Severity Scale scores and disease progression in patients with diabetic macular edema. METHODS: The 3-year, randomized, Phase 3 MEAD study evaluated DEX 0.35 and 0.7 mg versus sham (treatment at ≥6-month intervals) in patients with diabetic macular edema. This post hoc analysis used data from the sham and pooled DEX arms. RESULTS: The proportion of patients with ≥2-step Diabetic Retinopathy Severity Scale score improvement was significantly higher after DEX treatment compared with sham at 24 months only (8.8% vs. 4.2%, OR = 2.1, P = 0.016). Among those with ≥2-step Diabetic Retinopathy Severity Scale score improvement, the time to first ≥2-step improvement was shorter with DEX ( P < 0.001; median 400 days with DEX vs. 713 with sham). There were no significant differences between the DEX and sham groups in the proportion of patients who progressed from nonproliferative to proliferative diabetic retinopathy, but among those who progressed, the time to progression was lengthened with DEX ( P < 0.001; median 531.1 days with DEX vs. 191 with sham). CONCLUSION: This post hoc analysis of MEAD study data showed that DEX treatment may potentially have a positive impact on diabetic retinopathy by reducing disease severity and slowing progression in patients with diabetic retinopathy with central diabetic macular edema.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。